Genetic variations in methotrexate metabolic pathway genes influence methotrexate responses in rheumatoid arthritis patients in Malaysia
Abstract Methotrexate (MTX) is the most widely used disease-modifying anti-rheumatic drug (DMARD) for rheumatoid arthritis (RA). Many studies have attempted to understand the genetic risk factors that affect the therapeutic outcomes in RA patients treated with MTX. Unlike other studies that focus on...
Main Authors: | Hong Xi Sha, Kumar Veerapen, Sook Khuan Chow, Suk Chyn Gun, Ing Soo Lau, Renee Lay Hong Lim, Zaliha Zulkifli, Yoon-Yen Yow, Suat Cheng Peh, Jung Shan Hwang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-07-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-15991-0 |
Similar Items
-
Nano Methotrexate versus Methotrexate in Targeting Rheumatoid Arthritis
by: Heba F. Salem, et al.
Published: (2022-12-01) -
Methotrexate intolerance in Rheumatoid Arthritis
by: Harjit Singh Nalwa, et al.
Published: (2023-03-01) -
Methotrexate in Treatment of Rheumatoid Arthritis
by: Wiewiόrowski Maciej, et al.
Published: (1999-08-01) -
Infliximab and methotrexate in the treatment of rheumatoid arthritis
by: Lipsky, P, et al.
Published: (2000) -
Methotrexate dosage in the treatment of rheumatoid arthritis
by: Yuri Vladimirovich Muravyev
Published: (2013-11-01)